Business Wire

29 May 2026, 20:33 UTC · 2h ago

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Source · https://www.businesswire.com/news/home/20260529589368/en/Corcept-Presents-New-Data-at-ASCO-2026-Lifyorli%E2%84%A2-Overall-Survival-Across-All-Subgroups-of-Patients-with-Platinum-Resistant-Ovarian-Cancer-Including-Those-with-Recent-Taxane-Exposure/

Read source

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
Corcept Therapeutics presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli plus nab-paclitaxel at ASCO 2026. — Phase 3 survival data for a pivotal trial is a primary catalyst for biotech valuation and potential regulatory approval.
+0.50

Ticker attribution

Model heads

Sentiment in this article

CORT+0.60
The company presented new overall survival data from a pivotal Phase 3 trial for its drug Lifyorli.

Relationships in this article

No ticker relationship head found.

Impact vectors

3 dimensions · 9 clusters

6 related stories

PRNewsWire
13h ago
Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib
- asco
- biotech
- oncology
Read

News Impact Screener — Catch market-moving news before the crowd

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

What matters in this story

Sentiment in this article

Relationships in this article

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

What matters in this story

Sentiment in this article

Relationships in this article

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

PeproMene Bio anuncia una presentación oral en EHA 2026 donde destacará el PMB-CT01 en linfomas de células B

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

What matters in this story

Sentiment in this article

Relationships in this article

Next reads from the same story arc

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

What matters in this story

Sentiment in this article

Relationships in this article

Next reads from the same story arc

Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

PeproMene Bio anuncia una presentación oral en EHA 2026 donde destacará el PMB-CT01 en linfomas de células B

Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion